Case report of encapsulating peritoneal sclerosis: The interpretation of functional and structural peritoneal changes

Blood Purification

Volumn 26, Issue 1, 2008, Pages 12-17

  Diaz Buxo, Jose A ^a,b  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

^b NONE   (United States)

Author keywords

Dialysis complications; Encapsulating peritoneal sclerosis; Peritoneal biopsy; Peritoneal dialysis; Peritoneal transport; Peritonitis

Indexed keywords

ADOLESCENT; ANOREXIA; CAPILLARY DENSITY; CASE REPORT; CELL INFILTRATION; CHRONIC GLOMERULONEPHRITIS; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE COURSE; ENCAPSULATING PERITONEAL SCLEROSIS; FEMALE; FIBROSIS; HUMAN; HUMAN TISSUE; HYPERTENSION; LABORATORY TEST; LAPAROTOMY; PERIPHERAL EDEMA; PERITONEAL BIOPSY; PERITONEAL CATHETER; PERITONEAL DIALYSIS; PERITONEAL EQUILIBRIUM TEST; PERITONEAL FLUID LEVEL; PERITONITIS; PRIORITY JOURNAL; SCLEROSIS; SMALL INTESTINE OBSTRUCTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; ULTRAFILTRATION; UREMIA; URINE VOLUME;

ADOLESCENT; FATAL OUTCOME; FEMALE; GLOMERULONEPHRITIS; HUMANS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONEUM; PERITONITIS; SCLEROSIS;

EID: 38049006494     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110557     Document Type: Conference Paper

References (43)

1. Davies SJ, Bryan J, Phillips L, Russell GI: Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996;11:498-506.
2. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, Hayakawa H, Osaka N, Yamamoto H, Ogawa A, Kubo H, Shigematsu T, Sakai O, Horiuchi S: Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997;51:182-186.
3. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470-479.
4. Breborowicz A, Oreopoulos DG: Is normal saline harmful to the peritoneum? Perit Dial Int 2005;25(suppl 4):S67-S70.
5. Krediet RT: The peritoneal membrane in chronic peritoneal dialysis. Kidney Int 1999;55:341-356.
6. Hirahara I, Kusano E, Yanagiba S, Miyata Y, Ando Y, Muto S, Asano Y: Peritoneal injury by methylglyoxal in peritoneal dialysis. Perit Dial Int 2006;26:380-392.
7. Wieslander A, Linden T, Kjellstrand P: Glucose degradation products in peritoneal dialysis fluids: how they can be avoided? Perit Dial Int 2001;21(suppl 3):S119-S124.
8. Albrektsson A, Bazargani F, Wieslander A, Braide M: Peritoneal dialysis fluid-induced angiogenesis in rat mesentery is increased by lactate in the presence or absence of glucose. ASAIO 2006;52:276-281.
9. Del Peso G, Fernandez-Reyes MJ, Hevia C, Bajo MA, Castro MJ, Cirugeda A, Sanchez-Tomero JA, Selgas R: Factors influencing peritoneal transport parameters during the first year on peritoneal dialysis: peritonitis is the main factor. Nephrol Dial Transplant 2005;20:1201-1206.
10. Zareie M, Keuning ED, ter Wee PM, Beelen RH, van den Born J: Peritoneal dialysis fluid-induced changes of the peritoneal membrane are reversible after peritoneal rest in rats. Nephrol Dial Transplant 2005;20:189-193.
11. Metcalfe DD, Baram D, Mekori YA: Mast cells. Physiol Rev 1997;77:1033-1079.
12. Jimenez-Heffernan JA, Bajo MA, Perna C, Del Peso G, Larrubia JR, Gamallo C, Sanchez-Tomero JA, Lopez-Cabrera M, Selgas R: Mast cell quantification in normal peritoneum and during peritoneal dialysis treatment. Arch Pathol Lab Med 2006;130:1188-1192.
13. Bird SD, Walker RJ: Mast cell histamine-induced calcium transients in cultured human peritoneal mesothelial cells. Perit Dial Int 1998;18:626-636.
14. Alscher DM, Braun N, Biegger D, Fritz P: Peritoneal mast cells in peritoneal dialysis patients, particularly in encapsulating peritoneal sclerosis patients. Am J Kidney Dis 2007;49:452-461.
15. Yamamoto T, Izumotani T, Otoshi T, Kim M: Morphological studies of mesothelial cells in CAPD effluent and their clinical significance. Am J Kidney Dis 1998;32:946-952.
16. Rodrigues A, Cabrita A, Maia P, Guimaraes S: Peritoneal rest may successfully recover ultrafiltration in patients who develop peritoneal hyperpermeability with time on continuous ambulatory peritoneal dialysis. Adv Perit Dial 2002;18:78-80.
17. Wrenger E, Baumann C, Behrend M, Zamore E, Schindler R, Brunkhorst R: Peritoneal mononuclear cell differentiation and cytokine production in intermittent and continuous automated peritoneal dialysis. Am J Kidney Dis 1998;31:234-241.
18. Kim YL, Kim SH, Kim JH, Kim SJ, Kim CD, Cho DK, Kim YJ, Moberly JB: Effects of peritoneal rest on peritoneal transport and peritoneal membrane thickening in continuous ambulatory peritoneal dialysis rats. Perit Dial Int 1999;19(suppl 2):S384-S387.
19. Miranda B, Selgas R, Celadilla O, Munoz J, Sanchez SL: Peritoneal resting and heparinization as an effective treatment for ultrafiltration failure in patients on CAPD. Contrib Nephrol. Basel, Karger, 1991, vol 89, pp 199-204.
20. De Alvaro F, Castro MJ, Dapena F, Bajo MA, Fernandez-Reyes MJ, Romero JR, Jimenez C, Miranda B, Selgas R: Peritoneal resting is beneficial in peritoneal hyperpermeability and ultrafiltration failure. Adv Perit Dial 1993;9:56-61.
21. Burkart J, Stallard R: Result of peritoneal membrane resting on dialysate CA-125 levels and PET results (abstract). Perit Dial Int 1997;17(suppl 1):S5.
22. Kawanishi H, Morriishi M: Epidemiology of encapsulating peritoneal sclerosis in Japan. Perit Dial Int 2005;25(suppl 4):S14-S18.
23. Swartz R, Messana J, Holmes C, Williams J: Biofilm formation on peritoneal catheters does not require the presence of infection. ASAIO Trans 1991;37:626-634.
24. Flessner MF, Credit K, Henderson K, Vanpelt HM, Potter R, He Z, Henegar J, Robert B: Peritoneal changes after exposure to sterile solutions by catheter. J Am Soc Nephrol 2007;18:2294-2302.
25. Diaz-Buxo JA: Peritoneal dialysis solutions low in glucose degradation products: clinical experience and outcomes. Adv Perit Dial 2007;23:132-134.
26. Diaz-Buxo JA, Gotloib L: Agents that modulate peritoneal membrane structure and function. Perit Dial Int 2007;27:16-30.
27. Gaggiotti E, Arduini A, Bonomini M, Valentini G, Sacchi G, Sansoni E, Salvo D, Di Paolo N: Prevention of peritoneal sclerosis: a new proposal to substitute glucose with carnitine dialysis solution (biocompatibility testing in vitro and in rabbits). Int J Artif Organs 2005;28:177-187.
28. Duman S, Sen S, Sozmen EY, Oreopoulos DG: Atorvastatin improves peritoneal sclerosis induced by hypertonic PD solution in rats. Int J Artif Organs 2005;28:170-176.
29. Duman S, Sen S, Duman C, Oreopoulos DG: Effect of valsartan versus lisinopril on peritoneal sclerosis in rats. Int J Artif Organs 2005;28:156-163.
30. Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S: Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int 2005;25(suppl 4):S39-S47.
31. Kawaguchi Y, Saito A, Kawanishi H, Nakayama M, Miyazaki M, Nakamoto H, Tranaeus A: Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int 2005;25(suppl 4):S83-S95.
32. Mori Y, Matsuo S, Sutoh H, Toriyama T, Kawahara H, Hotta N: A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone. Am J Kidney Dis 1997;30:275-278.
33. Wong CF, Beshir S, Khalil A, Pai P, Ahmad R: Successful treatment of encapsulating peritoneal sclerosis with azathioprine and prednisolone. Perit Dial Int 2005;25:285-287.
34. Diaz-Buxo JA: Peritoneal sclerosis in a woman on continuous cyclic peritoneal dialysis. Semin Dial 1992;5:317-320.
35. Clark CP, Vanderpool D, Preskitt JT: The response of retroperitoneal fibrosis to tamoxifen. Surgery 1991;109:502-506.
36. Allaria PM, Giangrande A, Gandini E, Pisoni IB: Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent? J Nephrol 1999;12:395-397.
37. Del Peso G, Bajo MA, Gil F, Aguilera A, Ros S, Costero O, Castro MJ, Selgas R: Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial 2003;19:32-35.
38. Evrenkaya TR, Atasoyu EM, Unver S, Basekim C, Baloglu H, Tulbek MY: Corticosteroid and tamoxifen therapy in sclerosing encapsulating peritonitis in a patient on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2004;19:2423-2424.
39. Eltoum MA, Wright S, Atchley J, Mason JC: Four consecutive cases of peritoneal dialysis-related encapsulating sclerosis treated successfully with tamoxifen. Perit Dial Int 2006;26:203-206.
40. Gotloib L, Wajsbrot V, Shostak A: A short review of experimental peritoneal sclerosis: from mice to men. Int J Artif Organs 2005;28:97-104.
41. Di Paolo N, Sacchi G, Garosi G, Taganelli P, Gaggiotti E: Simple peritoneal sclerosis and sclerosing peritonitis: related or distinct entities? Int J Artif Organs 2005;28:117-128.
42. Bertoli SV, Buzzi L, Ciurlino D, Maccario M, Traversi L, Martino S, Procaccio M: Histological and functional characteristics of peritoneal membrane in peritoneal sclerosis of PD patients. Int J Artif Organs 2005;28:112-116.
43. Del Peso G, Jimenez-Heffernan JA, Bajo MA, Hevia C, Aguilera A, Castro MJ, Sanchez-Tomero JA, Lopez-Cabrera M, Selgas R: Myofibroblastic differentiation in simple peritoneal sclerosis. Int J Artif Organs 2005;28:135-140.